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Abstract 
 
Objective(s) 
A sensitive liquid chromatographic method for the analysis of clarithromycin- a macrolide antibiotic- in 
human serum, using pre-column derivatization with 9-fluorenylmethyl chloroformate (FMOC-Cl) is 
described.  
Materials and Methods 
The method involved liquid–liquid extraction of the drug and an internal standard (amantadine) followed by 
pre-column derivatization of the analytes with FMOC-Cl. A mixture of 0.05 M phosphate buffer containing 
triethylamine (2 ml/l; pH 3.8) and methanol (17:83, v/v) was used as mobile phase and chromatographic 
separation was achieved on a Shimpack CLC-ODS column. The eluate was monitored by a fluorescence 
detector with respective excitation and emission wavelengths of 265 and 315 nm.  
Results 
The analytical method was linear over the concentration range of 0.025-10 µg/ml of clarithromycin in human 
serum with a limit of quantification of 0.025 µg/ml. The assay is sensitive enough to measure drug levels 
obtained in human single dose studies. 
Conclusion 
In the present method, sensitivity and the running time of analysis have been improved and successfully 
applied in a bioequivalence study of three different clarithromycin preparations in 12 healthy volunteers. 
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Introduction 
Clarithromycin is a macrolide antibiotic with 
improved acid stability, better oral absorption, 
lower frequency of gastrointestinal 
intolerance, longer half life and more 
antibacterial activity against some pathogens 
compared with erythromycin (1). Due to weak 
UV absorbance of macrolide antibiotics, it is 
difficult to develop a simple method for 
analysis of the drugs in biological fluids, using 
conventional UV detection, thus, high-
performance liquid chromatography (HPLC) 
with electrochemical detection (ED) is the 
standard method for analysis of the drugs in 
biological matrix. Several HPLC methods 
have been reported for analysis of 
clarithromycin in human serum, using EC         
(2-9), MS (10), UV (11) and fluorescence 
detections (12). Determination of the drug in 
serum samples, using HPLC with UV 
detection at 205 nm has been recently reported 
by Amini and Ahmadiani (11) and although 
limit of quantification (LOQ) of 31.25 ng/ml 
has been obtained, using injection volume of 
100  µl, due to weak UV absorbance of the 
drug, the system should be set at highest 
sensitivity. Furthermore, high background 
noises are provided at this wavelength which 
makes obtaining a stable baseline difficult. 
Also, two steps sample preparation including 
liquid-liquid extraction followed by back 
extraction into diluted acid and analytical 
running time of 11 min have been reported in 
their method. Different sensitivities 
(10.03  µg/ml (2), 0.5  µg/ml (3), 0.03  µg/ml 
(4), 0.1 µg/ml (6), 0.01 µg/ml (8), 0.15 µg/ml 
(9)) have been reported, using HPLC-ED 
methods. A very sensitive method (LOQ 
2.95 ng/ml) for analysis of the drug in human 
plasma by HPLC–MS has been published (10). 
Quantitative analysis of macrolide antibiotics 
including erythromycin, roxithromycin, 
azithromycin and clarithromycin in human 
serum  using  pre-column  derivatization  with        
9-fluorenylmethyl chloroformate (FMOC-Cl) 
and fluorescence detection has been reported 
by Torano and Guchelaar (12). In their 
method, however, the sensitivity of analysis is 
not enough for human pharmacokinetic studies 
following a single dose administration of the 
drug (LOQ 0.20 µg/ml, using 50 µl injections). 
Furthermore, long time is needed for sample 
preparation and for reaction of the macrolides 
with FMOC-Cl (40  min). Based on these 
above-mentioned studies, the present study 
describes an improved method for analysis of 
clarithromycin in human serum, using FMOC-
Cl as labeling agent and fluorescence 
detection. This method was applied for 
quantification of the drug in a bioequivalence 
study following oral administration of three 
different clarithromycin preparations in 12 
healthy volunteers. It should be emphasized 
that, less time is needed for sample preparation 
and derivatization reaction, whereas, 
sensitivity has been improved, and the running 
analysis time was reduced.  
 
Materials and Methods 
Chemicals 
Clarithromycin was the product of Abbott 
Pharmaceutical Company (Kent, UK). 
Amantadine (IS) and FMOC-Cl were the 
products of  Sigma (Sigma, St. Louis, MO, 
USA). HPLC grade methanol, monobasic 
sodium phosphate, phosphoric acid, anhydrous 
sodium sulfate, triethylamine and 
dichloromethane were provided by Merck 
(Darmstand, Germany). All reagents were of 
the maximum available purity and used 
without further purification. Water was glass-
double distilled and further purified for HPLC 
with  a  Maxima  purification  system                
(USF ELGA, England). 
 
Equipment 
The HPLC system used in our study, consisted 
of two pumps of Shimadzu LC-10A solvent 
delivery system, a system controller (SCL 
10AD), a spectroflurometric detector (RF-551) 
operated at an excitation and emission 
wavelengths of 265 and 315 nm respectively, a 
column oven (CTO-10A), a degasser (DGU-
3A) and a data processor (C-R4A); all from 
Shimadzu, Kyoto, Japan. The analytical 
column was a Shimpack CLC-ODS 
(Shimadzu, Kyoto, Japan), 150 mm × 4.6 mm 
id, 5 µm particle size which was protected by a 
Shim-pack G-ODS guard column 
(1 cm × 4.0 mm  id,  5 µm  particle  size).  A 
mixture of 0.05  M sodium phosphate buffer   
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containing triethylamine (2 ml/l; pH 3.8) and 
methanol (17:83, v/v) was used as the mobile 
phase. The column oven temperature was set 
at 58  °C and the mobile phase was filtered, 
degassed and pumped at a flow rate of 
2.0 ml/min. 
 
Solutions 
Stock solutions of clarithromycin (1000 µg/ml) 
and the IS (600  µg/ml) were prepared by 
dissolving the drugs in acetonitrile and 
distilled water, respectively. The 
clarithromycin stock solution was further 
diluted with acetonitrile to obtain the different 
working solutions ranging from 0.25 to 
100 µg/ml. The IS stock solution was diluted 
with distilled water to obtain working solution 
of 6 µg/ml. A 1000 µg/ml solution of FMOC-
Cl was prepared in acetonitrile. All solutions  
stored at 4 °C and were stable for at least 4 
weeks, except clarithromycin stock solution 
which was prepared freshly before the 
analysis. 
 
Extraction procedure and derivatization 
Serum samples stored at -40 °C until the time of 
assay. Frozen serum samples were thawed in 
water at 37 °C. Aliquots of blank, calibration 
standard or unknown human serum samples 
(1 ml)  were  pipetted  into  100 mm × 16 mm 
disposable glass tubes, containing 100  µl of 
working internal standard solution. The samples 
were mixed with 200 µl of a phosphate buffer 
(0.05  M; pH 3) and extracted with 5  ml of 
dichloromethane as extracting solvent. After 
vortex mixing for 30  sec and centrifugation 
(5 min  at  6000 × g)  the  organic  phase  was 
removed and evaporated to dryness under stream 
of nitrogen at 50  °C. The residue was 
reconstituted in 100 µl of the FMOC-Cl solution. 
Following addition of 25  µl phosphate buffer 
(0.05 M; pH 8.5) and brief mixing, the samples 
were kept at 60 °C for 15 min and then a volume 
of 20 µl of the reaction mixture was injected into 
the HPLC system. 
 
Preparation of calibration curve standards 
Samples for calibration curves were prepared 
within the concentration range of 0.025-
10  µg/ml. In disposable glass tubes 
(100 mm × 16 mm),  after  evaporation  of 
100  µl from each working solutions of the 
drug; under a gentle stream of nitrogen at 
50 °C, the residues were reconstituted in 1 ml 
of drug-free human serum and mixed for 
10 sec on a vortex mixer. The samples were 
subjected to extraction, derivatization and 
analysis as described above. 
 
Method validation 
Assay linearity was evaluated with nine 
calibration standards in duplicate, using blank 
serum samples obtained from healthy 
volunteers. Calibration curves (weighed 
regression line) were obtained by linear least-
squares regression analysis of plots of peak-
area ratio of clarithromycin to IS versus drug 
concentrations. Quality control samples used 
in method validation were prepared with the 
drug working solutions to make low 
(0.025  µg/ml), medium (0.5  µg/ml) and high 
(5 µg/ml) concentrations. Within and between 
day variations were determined by repeated 
analysis (n=6) of different concentrations of 
the drug in a single analytical run and in 10 
analytical runs, performed on different days 
respectively, using the same stock solutions 
and serum batches. The specificity of the 
method was examined by presence of 
disturbing endogenous peaks in twelve human 
serum samples from different volunteers. 
These samples were pretreated according to 
the sample preparation procedure except for 
the addition of the IS The absolute recoveries 
of clarithromycin at the above mentioned 
concentrations as well as the IS at applied 
concentration were calculated in replicates 
(n=5) by comparing the respective peak areas, 
obtained by derivatization of the extracted 
samples from serum, with those obtained after 
derivatization of the same amounts of 
unextracted solutions in acetonitrile. The limits 
of detection (LOD) and quantification were 
defined as the concentration of the drug giving 
a signal-to-noise ratio of 3:1 and 10:1 
respectively. The stability of solutions of 
clarithromycin and the IS was studied over a 
period of 4 weeks by comparing the peak areas 
at different times. The stability of the drug in 
serum samples was examined by comparing 
the determined concentration in different times 
up  to  30  days  maintenance  of  the  samples           
at -40  °C and following three thaw-freeze 
cycles.  
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Application of the method 
The present method was applied in a three-
way randomized crossover bioequivalence 
study of different clarithromycin preparations. 
Twelve male healthy volunteers aged 28.5±2.5 
years and weighing 69.3±6.1 kg with normal 
biochemical parameters were enrolled in this 
study. All subjects received a single oral dose 
of 500 mg clarithromycin from either Tehran 
Chimi (Tehran, Iran), Chimidaruo (Tehran, 
Iran) or Abbott (Kent, UK) pharmaceutical 
companies on 3 working days separated by a 
wash-out period of 2 weeks. All the subjects 
were asked to refrain from food or water 
consumption for 3 hr after drug administration. 
Blood samplings were carried out at suitable 
intervals up to 24  hr and pharmacokinetic 
parameters including maximum concentration 
(Cmax), area under the concentration time 
curve from 0 to the time of last sampling 
(AUC0–t) and area under the concentration 
time curve from 0 to infinity (AUC0–∞) were 
compared. Bioequivalence between the 
preparations was determined by calculating 
90% confidence intervals for the ratio of 
Cmax, AUC0-t, and AUC0-∞ values for 
different products, using logarithmic 
transformed data. One-way analysis of 
variance (ANOVA) was used for the statistical 
analysis. Human study was approved by a 
local ethics committee. 
 
Results 
The reaction of clarithromycin and the IS with 
FMOC-Cl appeared to be highly dependent on 
pH of buffer solution (Figure 1A), time 
(Figure 1B), temperature (Figure 1C), 
concentration of the labeling agent (Figure 
1D), polarity of the medium (Figure 1E) and 
the  percentage of recovery (Table 1). 
 
Table 1. Polarity of the medium on the recovery of 
clarithromycin reacted with FMOC-Cl. 
 
 
 
Figure 1.  Effects of (A) pH of phosphate buffer, (B) 
time of derivatization, (C) temperature of reaction, (D) 
concentration of the labeling agent and (E) polarity of 
the medium on the reaction of clarithromycin with 
FMOC-Cl. 
 
The separation constant (K=drug 
concentration in organic phase/ drug 
concentration in aqueous phase) was 0.43. 
Based on the above-mentioned results, the 
optimal conditions were found to be: a buffer 
solution with pH of 8.5 consisting of water-
acetonitrile (1:5, v/v), a reaction temperature 
of 60  °C for 15  min and the reagent 
concentration of 1000 µg/ml. 
Typical chromatograms of human blank serum 
and human blank serum spiked with 
clarithromycin (0.05  µg/ml) and the IS are 
shown in Figure 2A and B respectively. 
Clarithromycin and the IS were eluted with 
respective retention times of 6.6 and 5.5 min. No 
endogenous substance from the plasma 
components was eluted in the retention times of 
clarithromycin or the IS. Figure 2C and D show 
the chromatograms of serum samples obtained at 
5 and 24 hr after a single oral dose of 500 mg 
clarithromycin from a healthy volunteer. The 
following drugs were tested for selectivity study 
and none of them were interfered with analysis 
of the drug, using the described method: 
acetaminophen, amoxicillin, cefalexin, 
cefradine, ceftriaxone, theophylline, acyclovir, 
codeine, caffeine, diclofenac, diazepam, 
nalidixic acid, ciprofloxacin, fluconazole, 
ketoconazole, gentamicin, etidronate, 
alendronate, baclofen, topiramate, erythromycin, 
propranolol and azithromycin. 
Recovery (%)    R e c o v e r y              
(µg)   Drug  
Acetonitrile: 
Water Ratio  
30.1    301.0   1:1  
59.43    594.3    1:2  
75.47    754.7   1:3  
89.62    896.2   1:4  
100    1000    1:5  
69.81    698.1   1:6    
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Figure 2.  Typical chromatograms obtained from an 
extract of (A) human blank serum spiked with 
amantadine as the IS, (B) human blank serum spiked 
with 0.05 µg/ml clarithromycin and the IS and (C and 
D) serum samples from a volunteer 5 and 24 hr after a 
single oral dose of 500  mg drug containing 3.3 and 
0.38 µg/ml of clarithromycin respectively. 
 
LOD was approximately 0.01  µg/ml and 
LOQ was 0.025  µg/ml. The proposed HPLC 
method was linear over the concentration 
range of 0.025-10  µg/ml. The correlation 
coefficients (r) for calibration curves were 
equal to or more than 0.9982. Intra-assay 
reproducibility was determined for calibration 
curves prepared in the same day in replicate 
(n=6), using the same stock solutions.  
The intra-day average slope of the fitted 
straight lines was 0.0354±0.0014  µg/ml 
(CV=3.8%) and the mean intercept of the 
calibration curves was 3.28±0.16 (CV=4.2%). 
The  corresponding  mean  (±SD)  coefficient      
of the linear regression analysis was 
0.9966±0.007 (CV=0.7%). For calibration 
curves  prepared  on  different  days  (n=10),        
the mean±SD of results were as follows: 
slope = 0.0362±0.0016 µg/ml  (CV=4.8), 
coefficient of the linear regression 
analysis = 0.9956±0.008  (CV=0.8%)  and 
intercept = 3.11 ± 0.15 (CV=3.7%). 
Stock solutions of clarithromycin and the IS 
were stable for 4 and 60 days respectively, 
when stored at 4  °C and the derivatized 
solutions were found to be stable (>95%) for 
12  hr. After 60 days, the concentrations of 
clarithromycin in serum stored at -40 °C were 
found to be 101% of the initial values. The 
mean recoveries of clarithromycin and IS from 
serum were 93±4 and 90±3% respectively. 
The within day and between days accuracy 
and precision values of the assay method are 
presented in Table 2. The coefficient variation 
values of both within day and between days 
were all less than 16.6%, whereas, accuracy 
never deviated from 100% by more than 7.3%. 
 
 
Table 2. Inter- and intra-day precision and accuracy for determination of clarithromycin in human serum by the HPLC 
method. 
Known concentration 
(µg/ml) 
Concentration found 
(mean±SD) 
Coefficient of variation (%) 
 
Accuracy (%) 
 
Within-day (n=6)       
0.025 0.024±0.004  16.6  96.7 
0.5 0.49±0.039  7.9  98 
2 1.99±0.07 3.6  99.3 
5 4.97±0.12 2.4  99.3 
10 10.02±0.20 2.0  99.8 
Known concentration (µg/m) Concentration  found 
(mean±SD) 
Coefficient of variation (%) 
 
Accuracy (%) 
 
Between-day (n=10)       
0.025 0.023±0.004  16.0  94.7 
0.5 0.5±0.036  7.3  99.7 
2 1.97±0.06 3.0  98.2 
5 4.97±0.16 3.2  99.4 
10 10.1±0.23 2.6  98.9 
Accuracy has been calculated as a mean deviation from the nominal values. 
 
 
Application of the method 
The  developed  method  has  been  applied            
in a randomized crossover three-ways 
bioequivalence study of three different 
clarithromycin preparations. Typical serum 
concentration-time profiles for the preparations 
are presented in Figure 3 and pharmacokinetic 
parameters are summarized in Table 3.  
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Figure 3. Mean serum concentrations vs. time profiles 
of clarithromycin for three clarithromycin preparations 
in 12 human volunteers after administration of a single 
500  mg oral dose in 12 human volunteers after 
administration of a single 500 mg oral dose. 
 
 
Table 3. Mean (SD) pharmacokinetic parameters of 
clarithromycin for different clarithromycin preparations 
(pharmaceutical prep. 1=Abbott, pharmaceutical prep. 
2=Chimodaruo and pharmaceutical prep. 3=Tehran 
Shimi) in 12 human volunteers after administration of a 
single 500 mg oral dose. 
 
Parameter Prep. 
 
  
 1  2  3 
Tmax (hr)  2.7 (1.1)
a  1.92 (0.9)  3.0 (1.1) 
Cmax (µg/ml)  3.19 (0.50)  3.04 (0.69)  2.88 (0.62) 
AUC0–24 
(µg hr/ml) 
27.49 (6.03)  24.93 (0.58)  26.37 (0.83) 
AUC0–∞ 
(µg hr/ml) 
31.07 (0.96)  27.37 (0.64)  29.80 (0.91) 
T1/2 (hr)  6.9 (2.6)  6.6 (1.7)  7.2 (3.3) 
 
Tmax, time to maximum concentration; Cmax, 
maximum concentration; AUC, area under the 
concentration–time curve; T1/2, elimination half life. 
a Values in the parentheses are SD of the amounts in 12 
healthy volunteers.  
 
Discussion 
FMOC-Cl reacts with primary and secondary 
amines in alkaline conditions and less readily 
with hydroxyl groups (Figure 4). Analysis of 
macrolide antibiotics in human serum, using 
FMOC-Cl, as labeling agent, has been 
previously reported (12) and derivatization of 
azithromycin by this reagent, using off-line 
(13) and on-line (14) methods had been 
performed in our laboratory. Also, Tris (2,2′-
bipyridine) ruthenium (II) as labeling agent, 
has been used for the analysis of macrolide 
antibiotic, erythromycin A by HPLC, using 
electrogenerated chemiluminescence detection 
(15). 
 
 
Figure 4. Derivatization reaction of FMOC-Cl with an 
amine and an alcohol. 
 
  In our previously published method for the 
analysis of azithromycin (13), derivatization of 
the drug was easily performed, using FMOC-
Cl at concentration of 500 µg/ml, temperature 
of 40  °C and reaction time of 40  min. 
However, under these conditions, low serum 
levels of clarithromycin, which are usually 
found in single dose pharmacokinetic studies, 
can not be detected. Thus, higher 
concentrations of FMOC-Cl, as well as 
increasing temperature and time of reaction 
were examined. Concentrations of the labeling 
agent between the ranges of 500 and 
5000 µg/ml were tested and although the yield 
of reaction was increased at higher 
concentrations of FMOC-Cl, significant band-
broadening was seen for a large excess of the 
reagent which interfered with analysis of the 
low amounts of clarithromycin. The 
temperature of reaction between the range of 
40 and 80  °C and reaction time of 10 and 
60 min were studied. The reactions of FMOC-
Cl have been found to take place within an 
aqueous-organic phase system and due to the 
insolubility of FMOC-Cl and derivatization 
products in water, it is necessary to apply a 
reaction solution with high content of 
acetonitrile (80%, v/v). However, the organic 
phase is evaporated if high temperature 
reaction (more than 64 °C) or long incubation 
time is used. Hence, a solution of the labeling 
agent with concentration of 1000  µg/ml, 
temperature medium of 60 °C, and incubation 
time of 15  min were selected. In our 
previously published methods for the analysis 
of azithromycin, using an aqueous solution of 
the glycine, the excess of FMOC-Cl was   
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removed. Sufficient proportion of the organic 
phase is needed for the reaction of glycine 
with the reagent, however, in the present 
method due to application of higher reaction 
temperature and partial evaporation of the 
organic solvent, excess of FMOC-Cl does not 
react with glycine. Furthermore, due to the 
insolubility of FMOC-Cl and derivatization 
products in water, the clarithromycin peak is 
significantly reduced following addition of the 
aqueous solution of glycine to the reaction 
mixture. Comparing the chemical structures of 
clarithromycin and azithromycin (Figure 5A 
and B, respectively) shows that the hydroxyl 
group in the position of six of pentadecan has 
been substituted by methoxy group in the 
clarithromycin (arrow in Figure 5B). As there 
are more hydroxyl groups in the azithromycin, 
it seems that reaction between the reagent and 
azithromycin proceeds more efficiently in 
comparison to clarithromycin. Thus, LOQ of 
0.025  µg/ml was obtained for clarithromycin 
in the present study, while this value was 
0.01 µg/ml for azithromycin in our previously 
published method (13). Also, the LOQ of 
0.092 and 0.2 µg/ml have been reported in the 
method described by Torano and Guchelaar 
(12) for azithromycin and clarithromycin 
respectively. 
A number of drugs with secondary or 
primary  amines  or  hydroxyl  groups               
(eg erythromycin, beta-lactam antibiotics, 
etidronate, alendronate, aminoglycosides, 
topiramate, gabapentin and amantadine) were 
tested and amantadine (Figure 5C) was 
selected as internal standard, because of its 
suitable retention time. A mobile phase with at 
least 2 ml/l of triethylamine was necessary to 
separate the peaks of the drug and endogenous 
substance as well as excess of the reagent 
which were eluted at the first parts of 
chromatogram. Unlike the IS, retention 
 behavior of the drug was pH-dependent and 
its retention time was found to increase 
proportionally with the pH of the mobile 
phase. Thus, pH of 4.3 was selected for the 
mobile phase. 
 
 
 
Figure 5. Chemical structures of (A) clarithromycin, (B) 
azithromycin and (C) amantadine. 
 
Conclusion 
In conclusion, a sensitive and specific method 
has been described for the determination of 
clarithromycin in serum. This method has 
demonstrated to be suitable for its use in 
pharmacokinetic studies of clarithromycin. In 
comparison to the previously published 
method, analysis time and LOQ were 
improved, and less time is needed for 
derivatization of the drug in human serum. 
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